Analysts at Barclays initiated coverage on Alnylam Pharmaceuticals, Inc. ALNY with a Overweight rating.
The target price for Alnylam Pharmaceuticals is set to $125.
Alnylam Pharmaceuticals shares have gained 33.30% over the past 52 weeks, while the S&P 500 index has surged 12.49% in the same period.
Alnylam Pharmaceuticals' shares rose 1.43% to close at $106.91 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in